Full Generic Medicine Info
Dosage/Direction for Use

Non-productive cough
Adult: As 50 mg tab: 2 or 3 tabs daily at intervals of 8 or 12 hours. As 7.5 mg/5 mL syr: 15 mL up to 4 times daily.
Children <18 years. 1st trimester of pregnancy.
Special Precautions
Renal and hepatic impairment. Pregnancy (2nd to 3rd trimester) and lactation. Patient Counselling This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery.
Adverse Reactions
Significant: Somnolence, dizziness. Gastrointestinal disorders: Diarrhoea, nausea. Skin and subcutaneous tissue disorders: Urticaria, rash.
Symptoms: Drowsiness, dizziness, nausea, vomiting, diarrhoea, hypotension. Management: Symptomatic treatment. Administer activated charcoal or saline laxative, or perform gastric lavage. Monitor vital functions.
Drug Interactions
Concomitant use of expectorants may lead to retention of mucous in the respiratory system, which can increase the risk of bronchospasm and airway infection.
Butamirate is a non-narcotic antitussive which presents nonspecific anticholinergic and antispasmodic effect, facilitating respiration. It acts centrally by diminishing the tussigenic reflex, and peripherally via a bronchospasmolytic activity enhanced by an anti-inflammatory action.
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1.5 hours.
Distribution: Plasma protein binding: Approx 95%.
Metabolism: Undergoes hydrolysis to phenyl-2-butyric acid and diethylaminoethoxyethanol.
Excretion: Primarily via kidneys as metabolites. Plasma elimination half-life: Approx 13 hours.
Oral: Store below 30°C. Protect from light.
CIMS Class
Cough & Cold Preparations
ATC Classification
R05DB13 - butamirate ; Belongs to the class of other cough suppressants.
Disclaimer: This information is independently developed by CIMS based on butamirate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in